These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Colorectal microbicide design: triple combinations of reverse transcriptase inhibitors are optimal against HIV-1 in tissue explants. Herrera C, Cranage M, McGowan I, Anton P, Shattock RJ. AIDS; 2011 Oct 23; 25(16):1971-9. PubMed ID: 21811139 [Abstract] [Full Text] [Related]
46. Specific microbicides in the prevention of HIV infection. Kelly CG, Shattock RJ. J Intern Med; 2011 Dec 23; 270(6):509-19. PubMed ID: 21917029 [Abstract] [Full Text] [Related]
48. The rational design and development of a dual chamber vaginal/rectal microbicide gel formulation for HIV prevention. Ham AS, Nugent ST, Peters JJ, Katz DF, Shelter CM, Dezzutti CS, Boczar AD, Buckheit KW, Buckheit RW. Antiviral Res; 2015 Aug 23; 120():153-64. PubMed ID: 26093158 [Abstract] [Full Text] [Related]
49. Electrospun fibers for vaginal anti-HIV drug delivery. Blakney AK, Ball C, Krogstad EA, Woodrow KA. Antiviral Res; 2013 Dec 23; 100 Suppl():S9-16. PubMed ID: 24188701 [Abstract] [Full Text] [Related]
51. Acceptability of a non-woven device for vaginal drug delivery of microbicides or other active agents. Joanis CL, Hart CW. AIDS Behav; 2010 Jun 23; 14(3):600-6. PubMed ID: 20049522 [Abstract] [Full Text] [Related]
52. Women's interest in vaginal microbicides. Darroch JE, Frost JJ. Fam Plann Perspect; 1999 Jun 23; 31(1):16-23. PubMed ID: 10029928 [Abstract] [Full Text] [Related]